Does a clinical trial always test a medicine?

No. Devices, behavioral interventions and care processes can also be studied.

Is an AI accuracy benchmark a clinical trial?

Not simply because it uses medical data; prospective assignment to a health intervention is a defining distinction.

Does registration prove that a trial is high quality?

No. Registration improves transparency, while quality still depends on design, execution, analysis and reporting.

AI Glossary / Statistics and probability / Intermediate

Clinical trial

Definition

A clinical trial is a research study that prospectively assigns people, or groups of people, to one or more health-related interventions to evaluate their effects on health outcomes. Interventions can include medicines, devices, procedures, behavioral programs and changes in care delivery. A trial involving an AI system evaluates an intervention in a health setting; its clinical conclusions depend on the design, participants, outcomes and conduct of that particular study.

What it means

The defining feature is prospective assignment to an intervention. Researchers decide what intervention participants will receive under a study plan and then observe relevant outcomes. Clinical trials are not all randomized, blinded, drug-focused or divided into the familiar drug-development phases. A retrospective analysis of an AI model on stored scans is generally a model-validation study, not automatically a clinical trial. Even excellent predictive accuracy does not establish that using the model improves patient health or clinical decisions in practice.

How it works

Researchers specify the question, eligibility criteria, intervention, comparison, outcomes and analysis in a protocol. Appropriate ethical review, consent arrangements and registration support responsible and transparent research. In a randomized trial, a chance mechanism assigns interventions to reduce systematic baseline differences. Allocation concealment protects assignment before it occurs; blinding concerns knowledge afterward. The team follows participants, records benefits and harms, accounts for missing outcomes and analyses the prespecified comparison. Interpretation considers uncertainty, adherence, follow-up duration and whether the study population represents the intended setting. Reporting guidelines improve transparency but cannot repair a fundamentally weak design.

Three practical examples

Decision support: compare usual care with care supported by an AI alert, measuring a meaningful patient outcome and unintended consequences.
Behavioral intervention: evaluate a digital coaching program against a suitable comparison, with agreed follow-up and participant safeguards.
Care delivery: assign clinics to different appointment-support processes and assess patient attendance, workload and relevant health outcomes.

Think of it this way

Think of testing a new navigation aid during real journeys. Checking that it recognizes roads is useful, but a field study asks whether people using it reach their destination more safely or effectively. In healthcare, that practical comparison needs careful research design and participant protection because a plausible recommendation can still have unexpected effects.

Worked example

Consider an explicitly hypothetical randomized study of an alert-assisted care process. Each group has 200 participants with complete follow-up for a predefined adverse outcome. The alert group records 20 events and usual care records 30. Observed risks are 20/200 = 10% and 30/200 = 15%. The risk difference, alert minus usual care, is -5 percentage points. The risk ratio is 0.10/0.15 = 0.667, approximately. Thus the observed relative reduction is 33.3%, while the absolute reduction is 5 percentage points. These are distinct descriptions of the same counts. They do not by themselves establish statistical certainty, safety, generalizability or a recommendation to adopt the intervention. A full analysis needs uncertainty estimates, protocol context, harms and information about the trial's conduct.

Illustrative case study

Fictional case: Cedar Health Research develops a prioritization assistant whose retrospective predictions look promising. Instead of assuming that accuracy guarantees better care, its team designs a prospective comparison of the supported workflow and usual practice. It selects a patient-relevant primary outcome and records delayed reviews, unnecessary escalations and staff workload as additional measures. The protocol distinguishes assignment from actual system use so that non-adherence does not disappear from the report. When the study ends, the team evaluates benefits and harms together and checks whether participating clinics resemble the proposed deployment sites. This invented case illustrates research planning, not evidence that any product improves health.

Common misconceptions and mistakes

A clinical trial is not necessarily a randomized controlled trial. Randomization does not guarantee identical groups, and a nonsignificant result does not establish equivalence. Surrogate outcomes may not capture the outcomes patients value. Excluding participants after assignment can bias a comparison, especially when exclusions relate to treatment or prognosis. An AI system can change staff behavior, access patterns and workload in ways absent from an offline dataset. Modifying the system during a trial also complicates what intervention was actually evaluated. Document changes and interpret claims within the evaluated version and setting.

Business use

For businesses developing health technologies, clinical trials can provide evidence about whether an intervention works in its intended workflow and what consequences accompany it. Product planning should connect evidence needs to the proposed use, population and outcomes rather than treat a trial as a marketing label. Budget for follow-up, reliable measurement, transparent reporting and the possibility that results do not support the original hypothesis. Regulatory and ethical requirements depend on the setting and must be addressed through the applicable processes.

Check your understanding

In the worked example, why is the observed improvement not a 5% relative reduction?

Answer: Five percentage points is the absolute difference between 15% and 10%. Dividing that difference by the comparison risk of 15% gives a relative reduction of about one third. Both measures need context and uncertainty.

Related terms

Allocation concealment
External validity
Randomized controlled trial
blinding
informed consent
clinical outcome
intention-to-treat analysis
risk difference
risk ratio
trial registration

Learn next

compare randomized and observational designs, then study outcome selection, allocation concealment and missing data. For AI interventions, examine how a protocol defines the system version, user workflow and deployment setting. Read a complete trial report alongside its protocol to connect the original question with the reported analysis.

Sources

World Health Organization, Clinical trials: questions and answers: https://www.who.int/news-room/questions-and-answers/item/clinical-trials National Institutes of Health, Glossary of Common Terms: https://www.nih.gov/health-information/nih-clinical-research-trials-you/glossary-common-terms CONSORT and SPIRIT, guidance for trial reporting and protocols: https://www.consort-spirit.org/

Previous: Clifford's method Next: Clipped double-Q learning